A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease
The Prostate · 2023-06 · 83 (8) · 814-819
DOI: 10.1002/pros.24521 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Prostate, online erschienen am 26.03.2023. Verfasst von Jonathan Q Trinh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Adenoids, Prostatic Neoplasms, Carcinoma, Adenoid Cystic, Basal Cell Carcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Metastatic adenoid cystic (basal cell) carcinoma of the prostate is an exceedingly rare disease entity. As a result, no current consensus exists for optimal systemic therapy.
Methods
We present a patient with metastatic adenoid cystic (basal cell) carcinoma of the prostate who subsequently received systemic treatment, including chemotherapy and immunotherapy. We comprehensively reviewed all published data on therapy outcomes in advanced disease.
Results
Our patient benefited from combination chemotherapy (carboplatin and paclitaxel), with objective radiographic response and reduction in cancer‐related pain. However, chemotherapy was stopped due to cumulative neurotoxicity, and subsequent immunotherapy with atezolizumab did not produce any response. Our literature review revealed inconsistent outcomes with various treatments but showed most promise with chemotherapy. Targeted therapy and immunotherapy seem to benefit specific cases, and androgen deprivation therapy had minimal evidence of benefit.
Conclusion
Based on the findings of our case report and literature review, we suggest platinum‐based chemotherapy doublets as first‐line treatment for metastatic cases of adenoid cystic (basal cell) carcinoma of the prostate, reserving targeted therapy or immunotherapy for select cases based upon molecular profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Jonathan Q Trinh, Benjamin A Teply
Zitieren
APA
Trinh, J. Q., Lele, S. M., & Teply, B. A. (2023). A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease. The Prostate, 83(8), 814-819. https://doi.org/10.1002/pros.24521
Vancouver
Trinh JQ, Lele SM, Teply BA. A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease. The Prostate. 2023;83(8):814-819. doi:10.1002/pros.24521
BibTeX
@article{Trinh2023,
author = {Trinh, Jonathan Q and Lele, Subodh M and Teply, Benjamin A},
title = {A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease},
journal = {The Prostate},
year = {2023},
volume = {83},
number = {8},
pages = {814--819},
doi = {10.1002/pros.24521}
}
EUVIMED